DNBSEQ-G400 from Complete Genomics: Latest Sequencing Technologies—Part 5

Complete Genomics (an MGI company) released the DNBSEQ-G400 into the U.S. market this summer. DNBSEQ-G400 is a benchtop sequencer that uses MGI’S DNA Nanoball sequencing technology (DNBSEQ) that boasts low index hopping, low amplification bias, and low PCR amplification error accumulation. In addition, the instrument is capable of using an improved antibody-based chemistry, CoolMPS sequencing reagent, that reduces errors and improves the sequencing quality.

Read type and length...

Onso was the second sequencer Pacific Biosciences (PacBio) revealed during this year’s American Society of Human Genetics meeting (read about the first sequencer here). This benchtop sequencer uses sequencing by binding (SBB), a method unlike any other instrument on the market. SBB incorporates native nucleotides, has reduced molecular scarring, and reportedly results in significantly higher accuracy base calls than traditional short-read sequencers. The following sections highlight the important...

Pacific Biosciences (PacBio) revealed two new sequencers during this year’s American Society of Human Genetics meeting. The first instrument, Revio, which will be covered in this article, is a significant upgrade from their previous Sequel II device. It has lower costs, shorter run times, more SMRT Cells and zero-mode waveguides (ZMW), and significantly higher output compared to PacBio’s other sequencers.

Read type and length
As a part of PacBio’s long-read sequencing systems,...

There has been a flurry of activity among next-gen sequencing companies this year with a number of new sequencers being announced. In October, Oxford Nanopore Technologies (ONT) announced the release of their new device, the PromethION 2 (P2) Solo sequencer. The P2 Solo is a small, high-yield sequencer with considerably lower starting costs compared to some of its competitors; the starter pack for ONT’s latest device is priced around $10,455. Despite its small size, the P2 Solo stands as a valuable...

In the Fall of 2022 Illumina announced their newest pair of flagship sequencers: the NovaSeq X and the NovaSeq X Plus. Their development was part of Illumina’s pursuit of lowering the cost of sequencing by dropping the price to approximately $200 per genome. The major differences between Illumina’s previous top sequencer (the NovaSeq 6000) and the NovaSeq X and X Plus are that the new devices have more affordable and updated reagents, faster run times, and the ability to process data directly...